Search results | Actavis


Partnering Agreements with Actavis

This report provides all the information you require to better understand Actavis and its partnering interests and activities over the past seven years.


Merger news : Actavis eyes $3 billion bid for Almirall

Merger news: Rumors that Ireland-based Actavis  is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV.

Both, Actavis and Sanofi competing for Omega Pharma

Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland.

Actavis chasing Allergan also…which way will Allergan go?

Actavis Plc plans to approach Allergan Inc again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Pfizer is in talks to acquire Actavis

Pfizer Inc. has approached Actavis with a possibility to acquire the company.

Is Pfizer’s next acquisition target, Actavis?

Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.


Actavis is a top pharmaceutical company based in New Jersey, USA

Valeant, Actavis and Mylan fight over Pfizer’s Generic business

Drugmakers Valeant Pharmaceuticals International Inc , Actavis Plc and Mylan Inc have all expressed interest in buying Pfizer’s branded generics business, but no active discussions are going on at this time, according to three people close to the matter.

Partnering with Actavis: strengthening competitive position

Actavis is a top pharma company active in partnering, licensing and M&A in pharmaceuticals

Actavis Inc: Partnering activity 2005-2013

The partnering activities of the two companies Actavis and Watson since 2005 are reviewed here

Actavis: M&A activity 2005-2013

Actavis and Watson together have announced over 30 M&A deals since 2005, with some of the deals being the acquisition of Warner Chilcott, ANDRx and Actavis itself by Watson


Sorry, your search returned no results.


Actavis divests pharma business to TPG

Actavis will divest to TPG the pharma business currently known as Aptalis Pharmaceutical Technologies (Pharmatech) a pharmaceutical outsourcing and R&D business within Actavis’ subsidiary Aptalis operating in the United States, Canada and Europe.

Mayne acquires Doryx rights from Actavis

Actavis has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx

Actavis acquires Auden McKenzie for $461 million

Actavis and Auden Mckenzie have reached a definitive agreement, under which Actavis will acquire Auden Mckenzie for approximately £306 million

Actavis and Grunenthal terminate Cebranopadol pact

Grunenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol

Actavis agrees to acquire Allergan in $66 billion deal

Actavis and Allergan have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock

Actavis to acquire Rhythm Health for $40 million

Actavis announced that Actavis has been granted an exclusive option to acquire Rhythm Health.

Actavis acquires Durata Therapeutics for $675 million

Actavis and Durata Therapeutics have inked a definitive  agreement to acquire Durata Therapeutics for $675 million.

Impax buys two generic drugs from Actavis

Impax Laboratories has acquired from Actavis two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement.

Actavis enters into a settlement agreement with Valeant

Actavis has entered into an agreement with Valeant Pharmaceuticals to settle all outstanding patent litigation related to Actavis’ generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.

Actavis signs a pharma deal to acquire topical products from Akorn

Actavis has entered into pharma deal agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.